Skip to menu Skip to content Skip to footer

2021

Journal Article

Outcomes of artery embolisation for cystic fibrosis patients with haemoptysis: a 20-year experience at a major Australian tertiary centre

Semasinghe Bandaralage, Sahan P., Tay, George, Hay, Karen, Megram, Emma, Smith, Daniel, Gadowski, Tahlia, Wright, Eimear, France, Megan, Bell, Scott and Reid, David (2021). Outcomes of artery embolisation for cystic fibrosis patients with haemoptysis: a 20-year experience at a major Australian tertiary centre. Internal Medicine Journal, 51 (9), 1526-1529. doi: 10.1111/imj.15483

Outcomes of artery embolisation for cystic fibrosis patients with haemoptysis: a 20-year experience at a major Australian tertiary centre

2019

Journal Article

Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease

Tong, Koliarne, Barker, Daniel, France, Megan, Burr, Lucy, Greville, Hugh, Visser, Simone, Middleton, Peter, Wainwright, Claire, Dorahy, Douglas and Wark, Peter (2019). Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease. Journal of Cystic Fibrosis, 19 (3), 415-420. doi: 10.1016/j.jcf.2019.12.006

Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease

2013

Journal Article

Ivacaftor in severe cystic fibrosis lung disease and a G551D mutation

Wood, Michelle E., Smith, Daniel J., Reid, David W., Masel, Philip J., France, Megan W. and Bell, Scott C. (2013). Ivacaftor in severe cystic fibrosis lung disease and a G551D mutation. Respirology Case Reports, 1 (2), 52-54. doi: 10.1002/rcr2.27

Ivacaftor in severe cystic fibrosis lung disease and a G551D mutation